英国癌症研究中心和 Nxera Pharma 在 Basu 博士和 Nxera Pharma 博士的领导下，启动了针对各种癌症的口服 EP4 拮抗剂HTL0039732 1/2a 期试验。 Cancer Research UK and Nxera Pharma launch Phase 1/2a trial of oral EP4 antagonist HTL0039732 for various cancers, led by Dr. Basu and Dr.
联合王国的Nxera Pharma和癌症研究正在对HTL0039732进行第1/2阶段临床试验,HTL0039732是一名口服EP4对抗者,旨在治疗各种癌症。 Nxera Pharma and Cancer Research UK are conducting a Phase 1/2a clinical trial for HTL0039732, an oral EP4 antagonist aimed at treating various cancers. 审判于2023年8月开始,评估药物的安全性、可耐性、有效性,无论是单独还是与Atezolizumab一起进行。 The trial, which began in August 2023, assesses the drug's safety, tolerability, and effectiveness both alone and with atezolizumab. 该研究由 Bristi Basu 博士和 Debashis Sarker 博士领导，研究结果将在即将举行的 ESMO 大会上公布。 The research is led by Dr. Bristi Basu and Dr. Debashis Sarker, with findings to be presented at the upcoming ESMO Congress. 入学工作正在进行中。 Enrollment is ongoing.